Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populat

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure

(2013) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

(2012) et al.   EUROPEAN HEART JOURNAL

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

(2012) Marco Metra et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

(2012) John R Teerlink et al.   LANCET

National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008

(2011) Jersey Chen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes

(2010) G. Michael Felker et al.   Circulation-Heart Failure

Epidemiology and risk profile of heart failure

(2010) Anh L. Bui et al.   Nature Reviews Cardiology

Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)

(2009) Daniel E. Forman et al.   AMERICAN HEART JOURNAL

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) Sharon Ann Hunt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study

(2009) John R Teerlink et al.   LANCET